Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Inclusion Criteria: * Histological confirmation of a newly diagnosed high-grade glioma or diffuse intrinsic pontine glioma (DIPG) (Stratum A) * Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG) (Stratum B) * Participants must have a genomic (DNA and/or RNA) alteration (mutation, fusion, and/or amplification) involving PDGF-A, PDGF-B, PDGFR-A or PDGFR-B, as identified by tumor sequencing. * Age at enrollment: Greater than 1 year and less than 50 years * BSA (body surface area): BSA greater than 0.3 m2 * Karnofsky (Measure of performance for cancer patients where 100% represents perfect health) \> 50% for patients \> 16 years of age and Lansky (Measure of performance for pediatric cancer patients where 100% represents perfect health) \> 50% for patients \< 16 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. * Adequate bone marrow function per protocol * Adequate liver function per protocol * Adequate renal and metabolic function per protocol * Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications * No increase in steroid dose within the past 7 days * Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions. * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy. * Myelosuppressive chemotherapy: Must not have received within 3 weeks. * Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting. * Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy. * Radiation therapy: * Stratum A: ≥ 2 weeks and \</= to 12 weeks must have elapsed from radiation. * Stratum B: ≥ 2 weeks must have elapsed from focal radiation. * \> 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team. * Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed. * All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents. Exclusion Criteria: * Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded. * Patients with uncontrolled infection are excluded. * Patients receiving other anti-neoplastic agents are excluded. * Patients requiring strong CYP3A4 or PGP inhibitors are excluded (per protocol) * Patients requiring anticoagulation or with uncontrolled bleeding are excluded. * Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment. * Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded. * Previous hypersensitivity to rapamycin or rapamycin derivatives